review Open AccessTop 1% cited
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
Breast Cancer Research and Treatment · 2012 · Vol. 134(2) · pp. 459–478
Caitlin C. Murphy✉(The University of Texas Health Science Center at Houston)L. Kay Bartholomew(The University of Texas Health Science Center at Houston)Melissa Y. Carpentier(The University of Texas Health Science Center)Shirley M. Bluethmann(The University of Texas Health Science Center at Houston)Sally W. Vernon(The University of Texas Health Science Center)
Medication Adherence and ComplianceMale Breast Health StudiesBipolar Disorder and TreatmentMedicineBreast cancerHormonal therapyInternal medicineCINAHLDiscontinuationAdjuvant therapyOncologyTamoxifenPsycINFO
MeSH terms
Breast NeoplasmsClinical Trials as TopicFemaleHumansNeoplasms, Hormone-DependentChemotherapy, AdjuvantSurvivorsAntineoplastic Agents, HormonalMedication Adherence
Funding
- National Institutes of Health
- National Cancer Institute
Citations
712
FWCI
21.75
field-weighted impact
References
85
Percentile
100%
vs. same field & year
Citations per year
References
Adherence to tamoxifen over the five-year course
Breast Cancer Research and Treatment · 2006 · 319 citations
Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer
Breast Cancer Research and Treatment · 2010 · 872 citations
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
The Lancet Oncology · 2010 · 1,683 citations
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
BMJ · 2009 · 82,871 citations
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Journal of Clinical Epidemiology · 2009 · 19,782 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.